Innovative pipeline and generic assets are advancing, with R&D results entering the harvest period.
Key Pipeline
| Asset | Area | Indication | Stage |
|---|---|---|---|
| SK-08 | Nephrology | CKD | Phase II |
| SK-09 | Nephrology | Podocyte injury-related nephropathy | Phase I |
| Iopamidol | Imaging | CT enhancement | Passed consistency evaluation |
| New generics | Multi-area | Various | BE/Registration |
Development stages are subject to regulatory disclosures and company announcements.